I don't know exactly what phenotypic data 23andme gets but if it's through surveys then it probably isn't as good as the clinical data that, say, regeneron gets

I don't know exactly what phenotypic data 23andme gets but if it's through surveys then it probably isn't as good as the clinical data that, say, regeneron gets for its genetic center through partnerships with healthcare providers. Also 23andme's database is large but presumably much of their data is from young healthy people -- I don't know for sure but it seems a reasonable assumption. So it wouldn't be as useful in studying disease as the overall size of the dataset seems to suggest. It also isn't as useful as a company like decode or Genomics medicine Ireland that study more homogenous populations. And GWAS have been done for many years so much of the low hanging fruit is picked 23andmes database's best advantage is probably studying things like genetic basis of mild to moderate anxiety and depression as those diseases are probably more prevalent in their population than others. Plus those are complex polygenic traits so each individual gene would have a small effect size, so a big database like 23andmes would be useful However that isn't great for drug discovery because drugs only hit one target. A bunch of genes with small effect sizes won't support much of a drug dev program I may be wrong as I'm not familiar w 23andmes database but these are my deductions from what I do know